ANKHD1 is an S phase protein required for histone synthesis and DNA repair in multiple myeloma cells

Dhyani, Anamika; Favaro, Patrícia; Saad, Sara Teresinha Olalla

doi:10.1016/j.bcmd.2020.102460

Cited by 4 publications

(9 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Remarkably, the association of ANKHD1 expression with genes regulated in response to UV radiation suggests an involvement with the DNA damage process. Indeed, in multiple myeloma cells, ANKHD1 silencing was reported to lead to increased DNA damage (Dhyani et al, 2020). In non‐small cell lung cancer cells, the SMYD3/ANKHD1 axis was shown to confer cisplatin chemoresistance (Lv et al, 2021).…”

Section: Resultsmentioning

confidence: 99%

ANKHD1 contributes to the malignant phenotype of triple‐negative breast cancer cells

Almeida

Costa-Lotufo

et al. 2022

Cell Biology International

View full text Add to dashboard Cite

Ankyrin repeat and KH domain-containing protein 1, ANKHD1, has been identified as a regulator of signaling pathways and cellular processes of relevance in carcinogenesis. However, the role of ANKHD1 in breast cancer remains unclear.The aim of the present study was to characterize the expression pattern and involvement of ANKHD1 in the malignant phenotype of breast cancer cell lines and to investigate the clinical relevance of ANKHD1 in a breast cancer context. Gene and protein expressions were assessed in the cell lines by quantitative reverse transcription PCR and Western blot analysis, respectively, and ANKHD1 silencing through siRNA transfection was conducted for further in vitro functional assays. The expression of ANKHD1 was identified in non-tumorigenic breast epithelium and breast cancer cell lines, but differences in cellular localization were found among the neoplasia subtypes. ANKHD1 silencing reduced the viability, clonogenicity, and migration of triple-negative breast cancer (TNBC) cells. Bioinformatics analyses demonstrated that patients with triple-negative basal-like 2 and mesenchymal breast cancer subtypes had high ANKHD1 expression associated with poor recurrence-free survival. Therefore, these data indicate that ANKHD1 relevance in breast cancer varies among its subtypes, indicating the importance of ANKHD1 in TNBC.

show abstract

Section: Resultsmentioning

confidence: 99%

ANKHD1 contributes to the malignant phenotype of triple‐negative breast cancer cells

Almeida

Costa-Lotufo

et al. 2022

Cell Biology International

View full text Add to dashboard Cite

show abstract

“…However, the knockdown of ANKHD1 with a short hairpin RNA (shRNA) increases p21 levels and results in cells arresting in the S phase [ 34 ]. Conversely, ANKHD1 overexpression decreased the levels of p21 bound to proliferating cell nuclear antigen (PCNA), causing a decrease in DNA repair and enhanced progression through the S phase—ultimately leading to uncontrolled cellular proliferation ( Figure 8 ) [ 57 ].…”

Section: Role Of Ankhd1 In Signalling Pathwaysmentioning

confidence: 99%

“…Increased levels of ANKHD1 are also reported in prostate cancer cells [ 37 ], resulting in delayed cell cycle progression through the S phase and enhanced tumorigenicity in xenografts [ 51 ]. Furthermore, in multiple myeloma cells, ANKHD1 has been associated with promoting cell growth and division [ 34 , 36 , 57 ]. Colorectal cancer cells show increased levels of ANKHD1 and are associated with an increase in epithelial-to-mesenchymal transition, allowing increased cell mobility, possibly linking ANKHD1 to increased migration and the invasion of cancer cells [ 54 ].…”

Section: Role Of Ankhd1 In Cancermentioning

confidence: 99%

Evaluating the Molecular Properties and Function of ANKHD1, and Its Role in Cancer

Mullenger,

Zeidler,

Fragiadaki

2023

IJMS

View full text Add to dashboard Cite

Ankyrin repeat and single KH domain-containing protein 1 (ANKHD1) is a large, scaffolding protein composed of two stretches of ankyrin repeat domains that mediate protein–protein interactions and a KH domain that mediates RNA or single-stranded DNA binding. ANKHD1 interacts with proteins in several crucial signalling pathways, including receptor tyrosine kinase, JAK/STAT, mechanosensitive Hippo (YAP/TAZ), and p21. Studies into the role of ANKHD1 in cancer cell lines demonstrate a crucial role in driving uncontrolled cellular proliferation and growth, enhanced tumorigenicity, cell cycle progression through the S phase, and increased epithelial-to-mesenchymal transition. Furthermore, at a clinical level, the increased expression of ANKHD1 has been associated with greater tumour infiltration, increased metastasis, and larger tumours. Elevated ANKHD1 resulted in poorer prognosis, more aggressive growth, and a decrease in patient survival in numerous cancer types. This review aims to gather the current knowledge about ANKHD1 and explore its molecular properties and functions, focusing on the protein’s role in cancer at both a cellular and clinical level.

show abstract

“…Accordingly, other studies have expanded the repertoire of signaling pathways and cellular processes mediated by ANKHD1. It has been reported that ANKHD1 interacts and represses CDKN1A (also known as p21) expression, promoting cell cycle progression (29,30), and that ANKHD1 silencing induced DNA damage markers, and reduced core histones, PCNA expression and S-phase progression (31). In another context, ANKHD1 interacts with SMYD3, a lysine methyltransferase, and mediates the pro-migratory and pro-invasive phenotype through the activation of SMYD3-modulated genes, especially SNAI2 (also known as Slug) (32).…”

Section: Signaling Network and Cellular Process Regulated By Ankhd1mentioning

confidence: 99%

Emerging functions for ANKHD1 in cancer-related signaling pathways and cellular processes

Almeida

Machado-Neto

2020

BMB Rep.

View full text Add to dashboard Cite

ANKHD1 (ankyrin repeat and KH domain containing 1) is a large protein characterized by the presence of multiple ankyrin repeats and a K-homology domain. Ankyrin repeat domains consist of widely existing protein motifs in nature, they mediate protein-protein interactions and regulate fundamental biological processes, while the KH domain binds to RNA or ssDNA and is associated with transcriptional and translational regulation. In recent years, studies containing relevant information on ANKHD1 in cancer biology and its clinical relevance, as well as the increasing complexity of signaling networks in which this protein acts, have been reported. Among the signaling pathways of interest in oncology regulated by ANKHD1 are Hippo signaling, JAK/STAT, and STMN1. The scope of the present review is to survey the current knowledge and highlight future perspectives for ANKHD1 in the malignant phenotype of cancer cells, exploring biological, functional, and clinical reports of this protein in cancer. [BMB Reports 2020; 53(8): 413-418]

show abstract

ANKHD1 is an S phase protein required for histone synthesis and DNA repair in multiple myeloma cells

Cited by 4 publications

References 39 publications

ANKHD1 contributes to the malignant phenotype of triple‐negative breast cancer cells

ANKHD1 contributes to the malignant phenotype of triple‐negative breast cancer cells

Evaluating the Molecular Properties and Function of ANKHD1, and Its Role in Cancer

Emerging functions for ANKHD1 in cancer-related signaling pathways and cellular processes

Contact Info

Product

Resources

About